Viridian Historical Balance Sheet

0K1R Stock

14.62 0.09 0.62%

Trend analysis of Viridian Therapeutics balance sheet accounts such as Short Long Term Debt Total of 22.1 M, Other Current Liabilities of 47.2 M or Total Current Liabilities of 50.3 M provides information on Viridian Therapeutics' total assets, liabilities, and equity, which is the actual value of Viridian Therapeutics to its prevalent stockholders. By breaking down trends over time using Viridian Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Viridian Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Viridian Therapeutics is a good buy for the upcoming year.

Viridian Therapeutics Inventory

(5.66 Million)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Viridian Stock please use our How to Invest in Viridian Therapeutics guide.

About Viridian Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Viridian Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Viridian Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Viridian Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Viridian currently owns. An asset can also be divided into two categories, current and non-current.

Viridian Therapeutics Balance Sheet Chart

At this time, Viridian Therapeutics' Cash And Short Term Investments are comparatively stable compared to the past year. Common Stock Shares Outstanding is likely to gain to about 71.3 M in 2025, despite the fact that Net Debt is likely to grow to (74.6 M).

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Total Assets

Total assets refers to the total amount of Viridian Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Viridian Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Viridian Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Viridian Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Viridian Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Viridian Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Viridian Stock please use our How to Invest in Viridian Therapeutics guide.At this time, Viridian Therapeutics' Cash And Short Term Investments are comparatively stable compared to the past year. Common Stock Shares Outstanding is likely to gain to about 71.3 M in 2025, despite the fact that Net Debt is likely to grow to (74.6 M).

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	5.3M	21.0M	21.1M	22.1M
Total Assets	435.1M	490.4M	742.4M	779.5M

Short Long Term Debt Total Total Assets

Viridian Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Assets	Net Tangible Assets
Total Assets		0.4	0.98	0.85	1.0	0.94	-0.41	-0.77	-0.99	0.44	0.86	0.58	0.36	1.0	-0.61	0.99	0.89	-0.61	0.93	0.99	0.93	1.0	-0.37	0.93	0.08	0.95
Short Long Term Debt Total	0.4		0.41	0.72	0.37	0.41	-0.17	0.03	-0.39	-0.09	0.19	-0.02	-0.18	0.4	0.07	0.46	0.52	-0.02	0.45	0.42	0.7	0.4	0.62	0.42	0.09	0.39
Other Current Liab	0.98	0.41		0.85	0.98	0.89	-0.36	-0.68	-0.98	0.32	0.77	0.45	0.24	0.98	-0.6	0.99	0.89	-0.58	0.96	0.99	0.92	0.99	-0.36	0.93	-0.04	0.9
Total Current Liabilities	0.85	0.72	0.85		0.84	0.83	-0.46	-0.52	-0.82	0.39	0.67	0.51	0.33	0.85	-0.36	0.86	0.71	-0.42	0.79	0.85	0.96	0.85	0.15	0.76	0.21	0.78
Total Stockholder Equity	1.0	0.37	0.98	0.84		0.94	-0.41	-0.78	-0.99	0.44	0.86	0.58	0.37	1.0	-0.62	0.99	0.89	-0.62	0.93	0.99	0.92	1.0	-0.4	0.93	0.07	0.95
Property Plant And Equipment Net	0.94	0.41	0.89	0.83	0.94		-0.58	-0.74	-0.92	0.51	0.82	0.68	0.45	0.94	-0.53	0.94	0.79	-0.52	0.79	0.92	0.88	0.94	-0.27	0.83	0.22	0.91
Current Deferred Revenue	-0.41	-0.17	-0.36	-0.46	-0.41	-0.58		0.24	0.37	-0.22	-0.28	-0.45	-0.34	-0.41	-0.03	-0.4	-0.11	0.02	-0.16	-0.36	-0.37	-0.41	-0.08	-0.12	-0.41	-0.24
Net Debt	-0.77	0.03	-0.68	-0.52	-0.78	-0.74	0.24		0.76	-0.82	-0.98	-0.85	-0.76	-0.78	0.65	-0.71	-0.62	0.71	-0.62	-0.72	-0.6	-0.77	0.59	-0.71	-0.32	-0.85
Retained Earnings	-0.99	-0.39	-0.98	-0.82	-0.99	-0.92	0.37	0.76		-0.38	-0.84	-0.53	-0.3	-0.99	0.65	-0.98	-0.9	0.68	-0.93	-0.99	-0.91	-0.99	0.39	-0.94	-0.01	-0.94
Accounts Payable	0.44	-0.09	0.32	0.39	0.44	0.51	-0.22	-0.82	-0.38		0.78	0.95	0.97	0.44	-0.4	0.37	0.2	-0.45	0.24	0.37	0.35	0.43	-0.26	0.36	0.59	0.57
Cash	0.86	0.19	0.77	0.67	0.86	0.82	-0.28	-0.98	-0.84	0.78		0.83	0.7	0.86	-0.62	0.81	0.73	-0.71	0.72	0.81	0.75	0.85	-0.45	0.8	0.32	0.93
Non Current Assets Total	0.58	-0.02	0.45	0.51	0.58	0.68	-0.45	-0.85	-0.53	0.95	0.83		0.94	0.58	-0.44	0.52	0.31	-0.48	0.33	0.5	0.47	0.57	-0.27	0.44	0.56	0.66
Non Currrent Assets Other	0.36	-0.18	0.24	0.33	0.37	0.45	-0.34	-0.76	-0.3	0.97	0.7	0.94		0.37	-0.31	0.29	0.07	-0.36	0.13	0.28	0.26	0.36	-0.23	0.22	0.6	0.46
Cash And Short Term Investments	1.0	0.4	0.98	0.85	1.0	0.94	-0.41	-0.78	-0.99	0.44	0.86	0.58	0.37		-0.61	0.99	0.89	-0.62	0.93	0.99	0.93	1.0	-0.37	0.93	0.08	0.95
Net Receivables	-0.61	0.07	-0.6	-0.36	-0.62	-0.53	-0.03	0.65	0.65	-0.4	-0.62	-0.44	-0.31	-0.61		-0.58	-0.53	0.83	-0.58	-0.61	-0.45	-0.61	0.58	-0.67	0.09	-0.64
Common Stock Shares Outstanding	0.99	0.46	0.99	0.86	0.99	0.94	-0.4	-0.71	-0.98	0.37	0.81	0.52	0.29	0.99	-0.58		0.91	-0.55	0.94	0.99	0.94	0.99	-0.33	0.94	0.04	0.93
Non Current Liabilities Total	0.89	0.52	0.89	0.71	0.89	0.79	-0.11	-0.62	-0.9	0.2	0.73	0.31	0.07	0.89	-0.53	0.91		-0.52	0.93	0.91	0.87	0.9	-0.35	0.93	-0.13	0.9
Inventory	-0.61	-0.02	-0.58	-0.42	-0.62	-0.52	0.02	0.71	0.68	-0.45	-0.71	-0.48	-0.36	-0.62	0.83	-0.55	-0.52		-0.56	-0.61	-0.49	-0.61	0.47	-0.67	-0.06	-0.67
Other Current Assets	0.93	0.45	0.96	0.79	0.93	0.79	-0.16	-0.62	-0.93	0.24	0.72	0.33	0.13	0.93	-0.58	0.94	0.93	-0.56		0.96	0.9	0.94	-0.36	0.97	-0.04	0.89
Other Stockholder Equity	0.99	0.42	0.99	0.85	0.99	0.92	-0.36	-0.72	-0.99	0.37	0.81	0.5	0.28	0.99	-0.61	0.99	0.91	-0.61	0.96		0.93	0.99	-0.36	0.96	0.04	0.94
Total Liab	0.93	0.7	0.92	0.96	0.92	0.88	-0.37	-0.6	-0.91	0.35	0.75	0.47	0.26	0.93	-0.45	0.94	0.87	-0.49	0.9	0.93		0.93	-0.03	0.89	0.12	0.89
Total Current Assets	1.0	0.4	0.99	0.85	1.0	0.94	-0.41	-0.77	-0.99	0.43	0.85	0.57	0.36	1.0	-0.61	0.99	0.9	-0.61	0.94	0.99	0.93		-0.37	0.93	0.07	0.95
Short Term Debt	-0.37	0.62	-0.36	0.15	-0.4	-0.27	-0.08	0.59	0.39	-0.26	-0.45	-0.27	-0.23	-0.37	0.58	-0.33	-0.35	0.47	-0.36	-0.36	-0.03	-0.37		-0.4	0.19	-0.4
Common Stock	0.93	0.42	0.93	0.76	0.93	0.83	-0.12	-0.71	-0.94	0.36	0.8	0.44	0.22	0.93	-0.67	0.94	0.93	-0.67	0.97	0.96	0.89	0.93	-0.4		0.03	0.95
Other Assets	0.08	0.09	-0.04	0.21	0.07	0.22	-0.41	-0.32	-0.01	0.59	0.32	0.56	0.6	0.08	0.09	0.04	-0.13	-0.06	-0.04	0.04	0.12	0.07	0.19	0.03		0.17
Net Tangible Assets	0.95	0.39	0.9	0.78	0.95	0.91	-0.24	-0.85	-0.94	0.57	0.93	0.66	0.46	0.95	-0.64	0.93	0.9	-0.67	0.89	0.94	0.89	0.95	-0.4	0.95	0.17

Click cells to compare fundamentals

Viridian Therapeutics Account Relationship Matchups

Viridian Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	131.3M	203.7M	435.1M	490.4M	742.4M	779.5M
Short Long Term Debt Total	455K	520K	5.3M	21.0M	21.1M	22.1M
Other Current Liab	9.2M	10.5M	18.2M	23.3M	44.9M	47.2M
Total Current Liabilities	10.7M	13.6M	33.3M	26.6M	47.9M	50.3M
Total Stockholder Equity	120.0M	187.7M	395.1M	442.0M	671.6M	705.2M
Property Plant And Equipment Net	787K	2.1M	2.9M	3.3M	3.4M	3.6M
Current Deferred Revenue	5.0M	301K	289K	288K	259.2K	246.2K
Net Debt	(45.4M)	(41.8M)	(150.3M)	(81.8M)	(78.5M)	(74.6M)
Retained Earnings	(278.9M)	(358.3M)	(488.2M)	(725.9M)	(995.9M)	(946.1M)
Accounts Payable	670K	2.3M	14.2M	2.2M	2.1M	2.1M
Cash	45.9M	42.3M	155.6M	102.8M	99.6M	104.6M
Non Current Assets Total	1.6M	3.5M	10.5M	3.9M	3.9M	2.7M
Non Currrent Assets Other	857K	1.5M	7.6M	604K	501K	992.8K
Cash And Short Term Investments	127.6M	197.0M	424.6M	477.4M	717.6M	753.5M
Net Receivables	24K	108K	451K	102K	91.8K	87.2K
Common Stock Shares Outstanding	3.6M	11.9M	32.1M	44.8M	67.9M	71.3M
Liabilities And Stockholders Equity	131.3M	203.7M	435.1M	490.4M	742.4M	779.5M
Non Current Liabilities Total	544K	2.4M	6.7M	21.8M	22.9M	24.0M
Other Current Assets	2.0M	2.6M	6.5M	9.0M	20.9M	21.9M
Other Stockholder Equity	218.1M	412.1M	741.1M	960.5M	1.6B	1.7B
Total Liab	11.2M	16.0M	40.0M	48.4M	70.8M	74.3M
Total Current Assets	129.6M	200.2M	424.6M	486.5M	738.5M	775.4M
Short Term Debt	455K	520K	613K	843K	513K	487.4K
Common Stock	42K	239K	414K	540K	810K	850.5K
Net Tangible Assets	15.8M	(60.8M)	53.9M	252.9M	290.9M	305.4M
Property Plant Equipment	523K	787K	2.1M	2.9M	3.4M	3.5M
Short Term Investments	81.7M	154.7M	269.0M	374.5M	618.0M	648.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Viridian Stock Analysis

When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC